These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26296668)

  • 1. Synergistic effects of ceftriaxone and erythropoietin on neuronal and behavioral deficits in an MPTP-induced animal model of Parkinson's disease dementia.
    Huang CK; Chang YT; Amstislavskaya TG; Tikhonova MA; Lin CL; Hung CS; Lai TJ; Ho YJ
    Behav Brain Res; 2015 Nov; 294():198-207. PubMed ID: 26296668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
    Ho SC; Hsu CC; Pawlak CR; Tikhonova MA; Lai TJ; Amstislavskaya TG; Ho YJ
    Behav Brain Res; 2014 Jul; 268():177-84. PubMed ID: 24755306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone reverses deficits of behavior and neurogenesis in an MPTP-induced rat model of Parkinson's disease dementia.
    Hsieh MH; Meng WY; Liao WC; Weng JC; Li HH; Su HL; Lin CL; Hung CS; Ho YJ
    Brain Res Bull; 2017 Jun; 132():129-138. PubMed ID: 28576659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceftriaxone prevents and reverses behavioral and neuronal deficits in an MPTP-induced animal model of Parkinson's disease dementia.
    Hsu CY; Hung CS; Chang HM; Liao WC; Ho SC; Ho YJ
    Neuropharmacology; 2015 Apr; 91():43-56. PubMed ID: 25499022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone prevents the neurodegeneration and decreased neurogenesis seen in a Parkinson's disease rat model: An immunohistochemical and MRI study.
    Weng JC; Tikhonova MA; Chen JH; Shen MS; Meng WY; Chang YT; Chen KH; Liang KC; Hung CS; Amstislavskaya TG; Ho YJ
    Behav Brain Res; 2016 May; 305():126-39. PubMed ID: 26940602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroprotective effects of ceftriaxone treatment on cognitive and neuronal deficits in a rat model of accelerated senescence.
    Tikhonova MA; Ho SC; Akopyan AA; Kolosova NG; Weng JC; Meng WY; Lin CL; Amstislavskaya TG; Ho YJ
    Behav Brain Res; 2017 Jul; 330():8-16. PubMed ID: 28487222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MK-801 on recognition and neurodegeneration in an MPTP-induced Parkinson's rat model.
    Hsieh MH; Gu SL; Ho SC; Pawlak CR; Lin CL; Ho YJ; Lai TJ; Wu FY
    Behav Brain Res; 2012 Apr; 229(1):41-7. PubMed ID: 22227506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
    Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
    Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of D-cycloserine on MPTP-induced behavioral and neurological changes: potential for treatment of Parkinson's disease dementia.
    Ho YJ; Ho SC; Pawlak CR; Yeh KY
    Behav Brain Res; 2011 Jun; 219(2):280-90. PubMed ID: 21262271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.
    Hsieh MH; Ho SC; Yeh KY; Pawlak CR; Chang HM; Ho YJ; Lai TJ; Wu FY
    Pharmacol Biochem Behav; 2012 Jul; 102(1):64-71. PubMed ID: 22487770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis.
    Kadota T; Shingo T; Yasuhara T; Tajiri N; Kondo A; Morimoto T; Yuan WJ; Wang F; Baba T; Tokunaga K; Miyoshi Y; Date I
    Brain Res; 2009 Feb; 1254():120-7. PubMed ID: 19101524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoietin and GDNF enhance ventral mesencephalic fiber outgrowth and capillary proliferation following neural transplantation in a rodent model of Parkinson's disease.
    McLeod M; Hong M; Mukhida K; Sadi D; Ulalia R; Mendez I
    Eur J Neurosci; 2006 Jul; 24(2):361-70. PubMed ID: 16903847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tangeretin inhibits neurodegeneration and attenuates inflammatory responses and behavioural deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease dementia in rats.
    Yang JS; Wu XH; Yu HG; Teng LS
    Inflammopharmacology; 2017 Aug; 25(4):471-484. PubMed ID: 28577132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production.
    Genc S; Kuralay F; Genc K; Akhisaroglu M; Fadiloglu S; Yorukoglu K; Fadiloğlu M; Gure A
    Neurosci Lett; 2001 Feb; 298(2):139-41. PubMed ID: 11163297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson's disease in rats.
    Bisht R; Kaur B; Gupta H; Prakash A
    Neurotoxicology; 2014 Sep; 44():71-9. PubMed ID: 25053526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats.
    Erbaş O; Çınar BP; Solmaz V; Çavuşoğlu T; Ateş U
    Neuropeptides; 2015 Feb; 49():1-5. PubMed ID: 25464888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring attention in a Parkinson's disease rat model using the 5-arm maze test.
    Ho SC; Hsu CC; Yu CH; Huang WN; Tikhonova MA; Ho MC; Hung CS; Amstislavskaya TG; Ho YJ
    Physiol Behav; 2014 May; 130():176-81. PubMed ID: 24690450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery from experimental parkinsonism by intrastriatal application of erythropoietin or EPO-releasing neural precursors.
    Carelli S; Giallongo T; Viaggi C; Latorre E; Gombalova Z; Raspa A; Mazza M; Vaglini F; Di Giulio AM; Gorio A
    Neuropharmacology; 2017 Jun; 119():76-90. PubMed ID: 28373075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the expression of genes related to the system of amyloid-beta metabolism in the brain as a novel mechanism of ceftriaxone neuroprotective properties.
    Tikhonova MA; Amstislavskaya TG; Belichenko VM; Fedoseeva LA; Kovalenko SP; Pisareva EE; Avdeeva AS; Kolosova NG; Belyaev ND; Aftanas LI
    BMC Neurosci; 2018 Apr; 19(Suppl 1):13. PubMed ID: 29745864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.